Headache
A potential new paradigm for treating acute migraine: Timolol nasal spray
Affecting more than 1 billion people worldwide, migraine is among the most common neurological diseases. During their lives, 43% of women and 18% of men develop migraine.
Study: Pediatric migraine drugs more effective with vitamin supplements
Pregabalin and topiramate significantly reduced the frequency and intensity of migraines in children and adolescents, especially when combined with vitamin supplements, according to a meta-analysis published in JAMA Network Open.
Managing migraine pain before it begins: Understanding prodrome, early treatment options
Migraine is a complex neurological disease that disproportionately affects women during their most productive years.
Headache management in kids: ‘When to worry and what to do’
ORLANDO, Fla. — Although children often suffer from headache, there are few controlled trials that include this unique patient population, leaving clinicians to rely on their experience rather than data, according to a presenter.
Focus on access, health literacy to improve headache management in rural areas
ORLANDO, Fla. — To properly address headache care gaps in rural areas, clinicians must focus on boosting access, improving health literacy and formulating simple but informative plans for medication usage, according to a speaker.
FDA accepts resubmission of NDA for Axsome’s oral migraine treatment
The FDA has accepted the resubmission of a new drug application for a novel, oral therapeutic intended to treat individuals with acute migraine, according to the manufacturer.
Real-world data confirm benefits of ravulizumab for atypical hemolytic uremic syndrome
Adults and children with atypical hemolytic uremic syndrome who switched from eculizumab to ravulizumab had stable renal function and hematologic values with similar safety seen in clinical trials, according to data from a registry study.
Monoclonal antibody superior to placebo in reducing migraine frequency
In patients with difficult-to-treat migraine, IV infusion of a novel monoclonal antibody provided superior migraine frequency relief compared with placebo in as early as 4 weeks, data show.
Ubrogepant may stop migraine before headache onset
Prodromal treatment with 100 mg ubrogepant was associated with greater functionality, fewer activity limitations and a high degree of satisfaction at 24 hours in patients with migraine, according to research published in Neurology.
OASIS: Nonhormonal elinzanetant improves hot flashes, menopause-related quality of life
Once-daily oral elinzanetant was well tolerated and improved moderate to severe vasomotor symptom frequency and severity, sleep disturbances and menopause-related quality of life, according to results of two studies published in JAMA.